Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Grippferon
- Development stage
- Unknown
- Lead developer
- Firn-M
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intranasal
01
Overview
Grippferon is an antiviral and immunomodulatory biologic medication developed by the Russian pharmaceutical company Firn M. Its active ingredient is recombinant human interferon alfa-2b, produced via genetic engineering. The drug is administered intranasally as drops, spray, or ointment. Grippferon works by binding to the interferon alpha/beta receptor (IFNAR) on the surface of cells in the nasal mucosa. This binding activates a signaling cascade that induces an antiviral state, inhibits viral replication, and enhances the local immune response. It is approved in Russia for the prevention and treatment of influenza and acute respiratory viral infections (ARVI) in children and adults, including pregnant women. Research has also demonstrated its inhibitory effects against other respiratory pathogens, including atypical pneumonia (SARS/MERS) and bird flu.
- Brand names
- GrippferonГриппферон
- Other names
- recombinant human interferon alfa-2b
02
Targets
IFNAR (Immune system modulation via type I interferon receptor)
Beyond the preview
Go deeper on Grippferon.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Grippferon.